Rhythm Pharmaceuticals (RYTM) announced a proposed public offering of $150M of its common stock. All securities in the offering will be offered by Rhythm. Morgan Stanley, BofA Securities, Stifel and Wells Fargo Securities are acting as joint book-running managers for the proposed offering. Canaccord Genuity and Citizens Capital Markets are acting as lead managers for the offering.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals price target raised to $95 from $72 at Needham
- Rhythm Pharmaceuticals price target raised to $95 from $73 at BofA
- Rhythm Pharmaceuticals price target raised to $95 from $80 at Morgan Stanley
- Rhythm Pharmaceuticals price target raised to $123 from $94 at Stifel
- Rhythm Pharmaceuticals price target raised to $129 from $91 at Wells Fargo